MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
MaxCyte, Inc.NASDAQ: MXCT
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 21.1% from a year ago
Deferred revenue stood at $3.27M at the end of Q1 FY2026, down 21.1% from a year earlier and down 9.1% from the prior quarter.
Context
- Deferred revenue amounted to 1.7% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -21.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 3.6M USD
- Year-over-year change
- -31.5%
- 4-year CAGR
- -14.5%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.6M | -31.5% |
| FY2024 | 2024-12-31 | 5.25M | +3.6% |
| FY2023 | 2023-12-31 | 5.07M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 6.75M | — |
Deferred Revenue vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's Mar 2026 deferred revenue of $3.27M is the 2nd highest of the 11 companies compared; the peer median is $499.76K.
- Its year-over-year change of -21.1% is the 4th highest of 7, against a peer median of +12.2%.
- Deferred revenue amounts to 1.7% of total assets for MXCT, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $26.6M | — | — | 6.5% | |
| Mar 2026 | $3.27M | -21.1% | — | 1.7% | |
| Mar 2026 | $3.01M | +51.2% | +58.8% | 4.5% | |
| Mar 2026 | $2.95M | -52.4% | -18.4% | 1.7% | |
| Mar 2026 | $2.41M | +65.3% | — | 2.8% | |
| Dec 2025 | $534K | +281.4% | +43.2% | 0.3% | |
| Mar 2026 | $465.53K | -26.8% | — | 0.6% | |
| Mar 2026 | $402K | -94.7% | -74.1% | 0.7% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MXCT) | $499.76K | +12.2% | +12.4% | 0.7% | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47.78M | 11.07M | 46.51M | 27.88M | 20.07M |
| Short-term Investments | 207.26M | 216.28M | 121.78M | 126.6M | 82.98M |
| Net Receivables | 6.88M | 11.18M | 5.78M | 4.68M | 3.5M |
| Inventory | 5.2M | 8.58M | 12.23M | 8.91M | 7.55M |
| Other Current Assets | 0 | 1.91M | 3.9M | 3.61M | 4.28M |
| Total Current Assets | 270.43M | 252.27M | 190.19M | 171.68M | 118.37M |
| Property, Plant & Equipment (Net) | 13.37M | 33.58M | 34.75M | 30.47M | 28.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 650K |
| Long-term Investments | 0 | 0 | 42.94M | 35.78M | 52.57M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 316.7K | 809K | 388K | 1.53M | 2.47M |
| Total Non-current Assets | 13.69M | 34.39M | 78.08M | 67.79M | 84.14M |
| Total Assets | 284.12M | 286.65M | 268.27M | 239.47M | 202.51M |
| Account Payables | 1.82M | 292K | 743K | 1.36M | 1.4M |
| Short-term Debt | 0 | 0 | 0 | 864K | 1.46M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.75M | 0 | 5.07M | 5.25M | 3.6M |
| Other Current Liabilities | 0 | 6.71M | 0 | 8.3M | 7.81M |
| Total Current Liabilities | 15.62M | 15.43M | 17.86M | 15.78M | 14.27M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 450.2K | 1.32M | 283K | 274K | 263K |
| Total Non-current Liabilities | 5.61M | 17.26M | 18.25M | 17.44M | 16.75M |
| Total Liabilities | 21.22M | 32.69M | 36.11M | 33.22M | 31.02M |
| Common Stock | 1.01M | 1.02M | 1.04M | 1.06M | 1.07M |
| Retained Earnings | (114.3M) | (137.88M) | (175.8M) | (216.85M) | (261.48M) |
| Accumulated OCI | 0 | (0) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 262.9M | 253.97M | 232.17M | 206.25M | 171.49M |
| Total Debt | 5.68M | 16.1M | 18.74M | 18.03M | 17.94M |
| Net Debt | (42.1M) | 5.03M | (27.76M) | (9.85M) | (2.12M) |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.